알파 글루코시다아제 억제제 시장(2026-2030년)

The global alpha glucosidase inhibitors market is forecasted to grow by USD 507.2 mn during 2025-2030, accelerating at a CAGR of 2.2% during the forecast period. The report on the global alpha glucosidase inhibitors market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing global prevalence of type 2 diabetes and prediabetes, unique mechanism of action targeting postprandial hyperglycemia, favorable safety profile regarding hypoglycemia and weight.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.

Technavio's global alpha glucosidase inhibitors market is segmented as below:

By Disease Type

• Type 2 diabetes
• Dumping syndrome

By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

By Product Type

• Acarbose
• Miglitol
• Voglibose
• Combination drugs

Geography

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • The Netherlands
• Asia
• Rest of World (ROW)
• Rest of World (ROW)

This study identifies the emphasis on combination therapies and fixed-dose combinations as one of the prime reasons driving the global alpha glucosidase inhibitors market growth during the next few years. Also, focus on improving tolerability and patient-centric formulations and leveraging real-world evidence to define niche clinical value will lead to sizable demand in the market.

The report on the global alpha glucosidase inhibitors market covers the following areas:

• Global alpha glucosidase inhibitors market sizing
• Global alpha glucosidase inhibitors market forecast
• Global alpha glucosidase inhibitors market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global alpha glucosidase inhibitors market vendors that include Ajanta Pharma Ltd., Alkem Laboratories Ltd., Bayer AG, Cipla Inc., CSPC Pharmaceutical Group Ltd., Dr. Reddys Laboratories Ltd., Glenmark Pharmaceuticals Ltd., Intas Pharmaceuticals Ltd., Ipca Laboratories, Lupin Ltd., Macleods Pharmaceuticals Ltd., Mankind Pharma Ltd., Micro Labs Ltd., Sun Pharmaceutical Industries, Takeda Pharmaceutical Ltd., Teva Pharmaceutical Ltd., Torrent Pharmaceuticals Ltd., Viatris Inc., Wockhardt Ltd., Zydus Lifesciences Ltd.. Also, the global alpha glucosidase inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
  • Executive Summary - Chart on Market Overview
  • Executive Summary - Data Table on Market Overview
  • Executive Summary - Chart on Global Market Characteristics
  • Executive Summary - Chart on Market by Geography
  • Executive Summary - Chart on Market Segmentation by Disease Type
  • Executive Summary - Chart on Market Segmentation by Distribution Channel
  • Executive Summary - Chart on Market Segmentation by Product Type
  • Executive Summary - Chart on Incremental Growth
  • Executive Summary - Data Table on Incremental Growth
  • Executive Summary - Chart on Company Market Positioning

2 Technavio Analysis

• 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 2.2 Criticality of inputs and Factors of differentiation
• 2.3 Factors of disruption
• 2.4 Impact of drivers and challenges

3 Market Landscape

• 3.1 Market ecosystem
• 3.2 Market characteristics
• 3.3 Value chain analysis

4 Market Sizing

• 4.1 Market definition
• 4.2 Market segment analysis
  • Market segments
• 4.3 Market size 2025
• 4.4 Market outlook: Forecast for 2025-2030

5 Historic Market Size

• 5.1 Global Alpha Glucosidase Inhibitors Market 2020 - 2024
  • Historic Market Size - Data Table on Global Alpha Glucosidase Inhibitors Market 2020 - 2024 ($ million)
• 5.2 Disease Type segment analysis 2020 - 2024
  • Historic Market Size - Disease Type Segment 2020 - 2024 ($ million)
• 5.3 Distribution Channel segment analysis 2020 - 2024
  • Historic Market Size - Distribution Channel Segment 2020 - 2024 ($ million)
• 5.4 Product Type segment analysis 2020 - 2024
  • Historic Market Size - Product Type Segment 2020 - 2024 ($ million)
• 5.5 Geography segment analysis 2020 - 2024
  • Historic Market Size - Geography Segment 2020 - 2024 ($ million)
• 5.6 Country segment analysis 2020 - 2024
  • Historic Market Size - Country Segment 2020 - 2024 ($ million)

6 Qualitative Analysis

• 6.1 Impact of AI on Global Alpha Glucosidase Inhibitors Market
• 6.2 Impact of Geopolitical Conflicts on Global Alpha Glucosidase Inhibitors Market

7 Five Forces Analysis

• 7.1 Five forces summary
  • Five forces analysis - Comparison between 2025 and 2030
• 7.2 Bargaining power of buyers
  • Bargaining power of buyers - Impact of key factors 2025 and 2030
• 7.3 Bargaining power of suppliers
  • Bargaining power of suppliers - Impact of key factors in 2025 and 2030
• 7.4 Threat of new entrants
  • Threat of new entrants - Impact of key factors in 2025 and 2030
• 7.5 Threat of substitutes
  • Threat of substitutes - Impact of key factors in 2025 and 2030
• 7.6 Threat of rivalry
  • Threat of rivalry - Impact of key factors in 2025 and 2030
• 7.7 Market condition

8 Market Segmentation by Disease Type

• 8.1 Market segments
• 8.2 Comparison by Disease Type
• 8.3 Type 2 diabetes - Market size and forecast 2025-2030
• 8.4 Dumping syndrome - Market size and forecast 2025-2030
• 8.5 Market opportunity by Disease Type
  • Market opportunity by Disease Type ($ million)

9 Market Segmentation by Distribution Channel

• 9.1 Market segments
• 9.2 Comparison by Distribution Channel
• 9.3 Hospital pharmacies - Market size and forecast 2025-2030
• 9.4 Retail pharmacies - Market size and forecast 2025-2030
• 9.5 Online pharmacies - Market size and forecast 2025-2030
• 9.6 Market opportunity by Distribution Channel
  • Market opportunity by Distribution Channel ($ million)

10 Market Segmentation by Product Type

• 10.1 Market segments
• 10.2 Comparison by Product Type
• 10.3 Acarbose - Market size and forecast 2025-2030
• 10.4 Miglitol - Market size and forecast 2025-2030
• 10.5 Voglibose - Market size and forecast 2025-2030
• 10.6 Combination drugs - Market size and forecast 2025-2030
• 10.7 Market opportunity by Product Type
  • Market opportunity by Product Type ($ million)

11 Customer Landscape

• 11.1 Customer landscape overview
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

12 Geographic Landscape

• 12.1 Geographic segmentation
• 12.2 Geographic comparison
• 12.3 North America - Market size and forecast 2025-2030
  • 12.3.1 US - Market size and forecast 2025-2030
  • 12.3.2 Canada - Market size and forecast 2025-2030
  • 12.3.3 Mexico - Market size and forecast 2025-2030
• 12.4 Europe - Market size and forecast 2025-2030
  • 12.4.1 Germany - Market size and forecast 2025-2030
  • 12.4.2 France - Market size and forecast 2025-2030
  • 12.4.3 UK - Market size and forecast 2025-2030
  • 12.4.4 Italy - Market size and forecast 2025-2030
  • 12.4.5 Spain - Market size and forecast 2025-2030
  • 12.4.6 The Netherlands - Market size and forecast 2025-2030
• 12.5 Asia - Market size and forecast 2025-2030
  • 12.5.1 China - Market size and forecast 2025-2030
  • 12.5.2 Japan - Market size and forecast 2025-2030
  • 12.5.3 India - Market size and forecast 2025-2030
  • 12.5.4 South Korea - Market size and forecast 2025-2030
  • 12.5.5 Indonesia - Market size and forecast 2025-2030
  • 12.5.6 Thailand - Market size and forecast 2025-2030
• 12.6 Rest of World (ROW) - Market size and forecast 2025-2030
  • 12.6.1 Brazil - Market size and forecast 2025-2030
  • 12.6.2 Saudi Arabia - Market size and forecast 2025-2030
  • 12.6.3 Turkey - Market size and forecast 2025-2030
  • 12.6.4 Argentina - Market size and forecast 2025-2030
  • 12.6.5 UAE - Market size and forecast 2025-2030
  • 12.6.6 South Africa - Market size and forecast 2025-2030
  • 12.6.7 Colombia - Market size and forecast 2025-2030
  • 12.6.8 Israel - Market size and forecast 2025-2030
• 12.7 Market opportunity by geography
  • Market opportunity by geography ($ million)
  • Data Tables on Market opportunity by geography ($ million)

13 Drivers, Challenges, and Opportunity

• 13.1 Market drivers
  • Increasing global prevalence of type 2 diabetes and prediabetes
  • Unique mechanism of action targeting postprandial hyperglycemia
  • Favorable safety profile regarding hypoglycemia and weight
• 13.2 Market challenges
  • Gastrointestinal side effects and patient adherence
  • Competition from newer antidiabetic agents
  • Modest glycemic efficacy and limited systemic benefits
• 13.3 Impact of drivers and challenges
  • Impact of drivers and challenges in 2025 and 2030
• 13.4 Market opportunities
  • Emphasis on combination therapies and fixed-dose combinations
  • Focus on improving tolerability and patient-centric formulations
  • Leveraging real-world evidence to define niche clinical value

14 Competitive Landscape

• 14.1 Overview
• 14.2 Competitive Landscape
  • Overview on criticality of inputs and factors of differentiation
• 14.3 Landscape disruption
  • Overview on factors of disruption
• 14.4 Industry risks
  • Impact of key risks on business

15 Competitive Analysis

• 15.1 Companies profiled
  • Companies covered
• 15.2 Company ranking index
  • Company ranking index
• 15.3 Market positioning of companies
  • Matrix on companies position and classification
• 15.4 Bayer AG
  • Bayer AG - Overview
  • Bayer AG - Business segments
  • Bayer AG - Key news
  • Bayer AG - Key offerings
  • Bayer AG - Segment focus
  • SWOT
• 15.5 Cipla Inc.
  • Cipla Inc. - Overview
  • Cipla Inc. - Business segments
  • Cipla Inc. - Key news
  • Cipla Inc. - Key offerings
  • Cipla Inc. - Segment focus
  • SWOT
• 15.6 CSPC Pharmaceutical Group Ltd.
  • CSPC Pharmaceutical Group Ltd. - Overview
  • CSPC Pharmaceutical Group Ltd. - Business segments
  • CSPC Pharmaceutical Group Ltd. - Key offerings
  • CSPC Pharmaceutical Group Ltd. - Segment focus
  • SWOT
• 15.7 Dr. Reddys Laboratories Ltd.
  • Dr. Reddys Laboratories Ltd. - Overview
  • Dr. Reddys Laboratories Ltd. - Business segments
  • Dr. Reddys Laboratories Ltd. - Key news
  • Dr. Reddys Laboratories Ltd. - Key offerings
  • Dr. Reddys Laboratories Ltd. - Segment focus
  • SWOT
• 15.8 Glenmark Pharmaceuticals Ltd.
  • Glenmark Pharmaceuticals Ltd. - Overview
  • Glenmark Pharmaceuticals Ltd. - Product / Service
  • Glenmark Pharmaceuticals Ltd. - Key news
  • Glenmark Pharmaceuticals Ltd. - Key offerings
  • SWOT
• 15.9 Ipca Laboratories
  • Ipca Laboratories - Overview
  • Ipca Laboratories - Product / Service
  • Ipca Laboratories - Key offerings
  • SWOT
• 15.10 Lupin Ltd.
  • Lupin Ltd. - Overview
  • Lupin Ltd. - Business segments
  • Lupin Ltd. - Key news
  • Lupin Ltd. - Key offerings
  • Lupin Ltd. - Segment focus
  • SWOT
• 15.11 Mankind Pharma Ltd.
  • Mankind Pharma Ltd. - Overview
  • Mankind Pharma Ltd. - Business segments
  • Mankind Pharma Ltd. - Key news
  • Mankind Pharma Ltd. - Key offerings
  • Mankind Pharma Ltd. - Segment focus
  • SWOT
• 15.12 Sun Pharmaceutical Industries
  • Sun Pharmaceutical Industries - Overview
  • Sun Pharmaceutical Industries - Business segments
  • Sun Pharmaceutical Industries - Key news
  • Sun Pharmaceutical Industries - Key offerings
  • Sun Pharmaceutical Industries - Segment focus
  • SWOT
• 15.13 Takeda Pharmaceutical Ltd.
  • Takeda Pharmaceutical Ltd. - Overview
  • Takeda Pharmaceutical Ltd. - Business segments
  • Takeda Pharmaceutical Ltd. - Key news
  • Takeda Pharmaceutical Ltd. - Key offerings
  • Takeda Pharmaceutical Ltd. - Segment focus
  • SWOT
• 15.14 Teva Pharmaceutical Ltd.
  • Teva Pharmaceutical Ltd. - Overview
  • Teva Pharmaceutical Ltd. - Business segments
  • Teva Pharmaceutical Ltd. - Key news
  • Teva Pharmaceutical Ltd. - Key offerings
  • Teva Pharmaceutical Ltd. - Segment focus
  • SWOT
• 15.15 Torrent Pharmaceuticals Ltd.
  • Torrent Pharmaceuticals Ltd. - Overview
  • Torrent Pharmaceuticals Ltd. - Product / Service
  • Torrent Pharmaceuticals Ltd. - Key offerings
  • SWOT
• 15.16 Viatris Inc.
  • Viatris Inc. - Overview
  • Viatris Inc. - Business segments
  • Viatris Inc. - Key news
  • Viatris Inc. - Key offerings
  • Viatris Inc. - Segment focus
  • SWOT
• 15.17 Wockhardt Ltd.
  • Wockhardt Ltd. - Overview
  • Wockhardt Ltd. - Business segments
  • Wockhardt Ltd. - Key offerings
  • Wockhardt Ltd. - Segment focus
  • SWOT
• 15.18 Zydus Lifesciences Ltd.
  • Zydus Lifesciences Ltd. - Overview
  • Zydus Lifesciences Ltd. - Business segments
  • Zydus Lifesciences Ltd. - Key news
  • Zydus Lifesciences Ltd. - Key offerings
  • Zydus Lifesciences Ltd. - Segment focus
  • SWOT

16 Appendix

• 16.1 Scope of the report
  • Market definition
  • Objectives
  • Notes and caveats
• 16.2 Inclusions and exclusions checklist
  • Inclusions checklist
  • Exclusions checklist
• 16.3 Currency conversion rates for US$
  • Currency conversion rates for US$
• 16.4 Research methodology
  • Research methodology
• 16.5 Data procurement
  • Information sources
• 16.6 Data validation
  • Data validation
• 16.7 Validation techniques employed for market sizing
  • Validation techniques employed for market sizing
• 16.8 Data synthesis
  • Data synthesis
• 16.9 360 degree market analysis
  • 360 degree market analysis
• 16.10 List of abbreviations
  • List of abbreviations